Bausch + Lomb's Q4 2024: Contradictions in Growth Expectations, Miebo Coverage, and Xiidra Performance
Earnings DecryptWednesday, Feb 19, 2025 12:24 pm ET
1min read
These are the key contradictions discussed in Bausch + Lomb's latest 2024Q4 earnings call, specifically including: Growth Expectations and Market Conditions, Managed Care Coverage for MIEBO, and Xiidra's Integration and Performance:
Revenue Growth and Market Share:
- Bausch + Lomb reported 17% constant currency revenue growth for the year, contributing to double-digit constant currency revenue growth for the fifth consecutive quarter.
- The growth was driven by introducing new products, optimizing manufacturing processes, and leveraging digital tools for increased customer engagement.
Dry Eye Portfolio Expansion:
- The company's dry eye portfolio approached $1 billion in annual revenue, with nearly 50% year-over-year growth in organic revenue.
- This growth was fueled by effective direct-to-consumer campaigns and strong prescriber education for both Miebo and Xiidra.
Contact Lens Performance:
- Bausch + Lomb's contact lens revenue grew 11% for the year, with strong performance across modalities, brands, and geographies.
- Growth was broad-based, driven by the Daily SiHy lens and the company's e-commerce platform, Opal, which opened new distribution channels.
Premium IOL and Surgical Segment Growth:
- The surgical segment saw 11% organic revenue growth, driven by 19% growth in premium IOLs and 21% growth in equipment sales.
- The growth in premium IOLs was attributed to new product launches like Envy and LuxLife, which are being well-received by surgeons and patients.
Revenue Growth and Market Share:
- Bausch + Lomb reported 17% constant currency revenue growth for the year, contributing to double-digit constant currency revenue growth for the fifth consecutive quarter.
- The growth was driven by introducing new products, optimizing manufacturing processes, and leveraging digital tools for increased customer engagement.
Dry Eye Portfolio Expansion:
- The company's dry eye portfolio approached $1 billion in annual revenue, with nearly 50% year-over-year growth in organic revenue.
- This growth was fueled by effective direct-to-consumer campaigns and strong prescriber education for both Miebo and Xiidra.
Contact Lens Performance:
- Bausch + Lomb's contact lens revenue grew 11% for the year, with strong performance across modalities, brands, and geographies.
- Growth was broad-based, driven by the Daily SiHy lens and the company's e-commerce platform, Opal, which opened new distribution channels.
Premium IOL and Surgical Segment Growth:
- The surgical segment saw 11% organic revenue growth, driven by 19% growth in premium IOLs and 21% growth in equipment sales.
- The growth in premium IOLs was attributed to new product launches like Envy and LuxLife, which are being well-received by surgeons and patients.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet